EN DE

Aplisens S.A (APN) Fair Value & Analysis

Technology · PL · Market cap 217M PLN

AS Aplisens S.A APN · WAR
Price20.30 PLN
Fair Value31.10 PLN
Upside+53.2%
Quality64/100
Watch Aplisens S.A for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Solidly profitable · 10.4% net margin
generates free cash flow
4.59% dividend yield
Ranks above peers (12/13)
Moderate moat 47/100
Evidence: High Range 21.48 PLN – 42.47 PLN Share as image

Fair value as of: Aug 13, 2026

From 25 valuation models · updated today

Fair value updated Aug 13, 2026, revised from 27.40 PLN to 31.10 PLN (+13.5%) since Jul 16, 2026. Share price +3.6% over the past month.

A solid business, screening 53% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (21.48 PLN). The market is more pessimistic than our downside scenario.
  • Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.
  • A fairly wide model range (21.48 PLN to 42.47 PLN) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

22.76 PLN 8.69 PLN Fair Value 31.10 PLN May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 8.69 PLN – 22.76 PLN · fair‑value band 21.48 PLN – 42.47 PLN · the 20.30 PLN price screens below the 31.10 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Aplisens S.A (APN) currently trades at 20.30 PLN, while our model-based Fair Value estimate is 31.10 PLN, implying the stock looks roughly 53.2% undervalued today. The Quality Score stands at 64/100 (solid quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Aplisens S.A generated revenue of 147M PLN at a net margin of 10.4%. Revenue declined 0.1% year over year. It earns a return on equity of 6.7%. The balance sheet holds a net cash position of 14.6M PLN. Fundamentals as of Aug 13, 2026

Our scenario range runs from 21.48 PLN (bear case) to 42.47 PLN (bull case); at 20.30 PLN, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 22% above its 52-week low, currently above its 200-day average. For context, the median of 10 Technology peers we cover trades at -46% fair-value upside, at 53%, APN screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income 14.83 PLN 15.02 PLN 14.09 PLN 76
Growth DCF 18.98 PLN 24.54 PLN 30.94 PLN 72
Gordon GGM 4.88 PLN 8.17 PLN 10.60 PLN 70
All 25 models by family
DCF Models
FCF DCF 18.90 PLN 25.27 PLN 33.03 PLN 38
5Y Revenue Exit 17.13 PLN 24.70 PLN 34.09 PLN 39
5Y EBITDA Exit 26.14 PLN 41.27 PLN 58.65 PLN 41
5Y P/E Exit 23.18 PLN 35.84 PLN 48.85 PLN 38
10Y Revenue Exit 17.39 PLN 23.76 PLN 31.82 PLN 36
10Y EBITDA Exit 22.61 PLN 33.50 PLN 47.59 PLN 37
10Y P/E Exit 21.01 PLN 30.31 PLN 41.30 PLN 35
Earnings-Based
Graham-Dodd 9.32 PLN 26.85 PLN 35.42 PLN 54
Lynch FV 5.53 PLN 7.91 PLN 10.28 PLN 50
PEG = 1.0 5.53 PLN 7.91 PLN 10.28 PLN 46
EPV 11.12 PLN 12.30 PLN 13.25 PLN 59
Dividend Discount
Gordon GGM 4.88 PLN 8.17 PLN 10.60 PLN 70
DDM Multi-Stage 4.88 PLN 7.10 PLN 8.79 PLN 61
Multiples
P/E Multiple 28.77 PLN 38.36 PLN 47.96 PLN 63
P/S Multiple 17.47 PLN 23.29 PLN 29.12 PLN 58
P/B Multiple 17.47 PLN 23.29 PLN 29.12 PLN 55
EV/EBIT 31.64 PLN 41.74 PLN 51.85 PLN 53
EV/EBITDA 36.11 PLN 47.71 PLN 59.31 PLN 54
EV/Revenue 16.64 PLN 23.21 PLN 29.78 PLN 43
Asset-Based
NCAV (Graham) 10.19 PLN 13.65 PLN 20.38 PLN 50
Growth DCF
Growth DCF 18.98 PLN 24.54 PLN 30.94 PLN 72
Rev-Margin DCF 17.13 PLN 24.91 PLN 33.74 PLN 67
Economic Profit
Residual Income 14.83 PLN 15.02 PLN 14.09 PLN 76
ROIC Compounder 11.12 PLN 12.30 PLN 13.25 PLN 67
Growth Earnings
Growth-Adj P/E 22.63 PLN 32.33 PLN 42.02 PLN 68

Widest divergence: Growth Earnings (32.33 PLN) versus Dividend Discount (7.10 PLN). Highest evidence: Residual Income (76).

Notify me when APN reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 147M PLN
Revenue growth (YoY) -0.1%
Net margin 10.4%
Return on equity 6.7%
Free cash flow 24.0M PLN FY2025
P/E ratio 14.4
More key figures
Operating margin 13.7%
EPS (TTM) 1.41 PLN
Dividend yield 4.9%
EPS growth (YoY) -3.0%
Net cash 14.6M PLN FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 64/100

Of which business quality 65 · Market factors (momentum, volatility) 73

Profitability 42
Margins and returns on capital today
Quality Growth 18
Are margins and returns improving?
Cashflow 76
Earnings quality: real cash, not paper profit
Fin. Strength 84
Balance sheet, leverage, solvency risk
Investment 77
Disciplined investing over empire-building
Low Volatility 92
Calm price path (market factor)
Momentum 60
Price trend over the last 3–12 months (market factor)
52W Momentum 74
Distance to the 52-week high (market factor)
Net Issuance 91
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Aplisens S.A. supplies industrial control and measurement equipment in Poland, European Union, CIS countries, the United States, Asia, and internationally.

Full company description

Aplisens S.A. supplies industrial control and measurement equipment in Poland, European Union, CIS countries, the United States, Asia, and internationally. The company offers pressure, differential pressure, and level transducers; depth and level probes; electromagnetic flowmeters; measuring orifices; temperature sensors and transducers; valves and mounting accessories; meters, controllers, and displays; power supplies, separators, and signal transducers; fuel level probes for trucks; positioners; and electric actuators. It also provides consulting services related to the applications of its manufactured equipment; and warranty and post-warranty services. Its products are primarily focused on electronic pressure and differential pressure measurement technology. Aplisens S.A. was founded in 1992 and is headquartered in Warsaw, Poland.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Aplisens S.A reported revenue of 147M PLN in FY2025 versus 121M PLN in FY2021, a compound +4.8%/yr. Reported net income was 15.3M PLN in FY2025, compounding −3.0%/yr from FY2021.

Growth Quality 71/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
147M PLN
Latest YoY
−5.7%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−0.3%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+6.3%
Avg. growth/yr (17Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.2%
Revenue +4.8%/yr
FY21 121M PLN
FY22 148M PLN
FY23 163M PLN
FY24 155M PLN
FY25 147M PLN
Net income −3.0%/yr
FY21 17.2M PLN
FY22 20.4M PLN
FY23 31.6M PLN
FY24 20.7M PLN
FY25 15.3M PLN
Character of growth · EPS growth decomposed (2014-2025) +8.1 % p.a.
Revenue per share +8.4 pp

of which total revenue +6.1 pp · buybacks/dilution +2.3 pp

EBIT margin +0.0 pp
Tax rate −0.3 pp
Residual (interest, one-offs) +0.0 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch APN: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Aplisens S.A Fair Value". https://www.fairvalue-calculator.com/stock/APN

Peer Group

Scientific & Technical Instruments · 169 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 64 · Above median
Fair Value upside +53% · Top 25%
Return on equity (TTM) 7% · Above median
Return on assets 5% · Above median
Net margin (TTM) 10% · Above median
Operating margin (TTM) 14% · Above median
Revenue growth -0% · Below median
Dividend yield (TTM) 4.6% · Top 25%

Valuation Multiples vs Scientific & Technical Instruments median · lower = cheaper

P/E (TTM) 14.4× · Cheaper than 75% of peers
P/B 0.26× · Cheaper than 75% of peers
P/S (TTM) 0.40× · Cheaper than 75% of peers
P/FCF 2.4× · Cheaper than median
EV/EBITDA 1.5× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 0
FUTURE 0 · sector 27
PAST 27 · sector 23
HEALTH 0 · sector 98
DIVIDEND 92 · sector 19

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Scientific & Technical Instruments stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Keysight Technologies, Inc KEYS $354.50 $107.22 -70%
Garmin Ltd GRMN $309.98 $139.44 -55%
Teledyne Technologies Incorporated TDY $686.49 $488.95 -29%
Hexagon AB HEXAB kr 95.06 kr 73.99 -22%
MKS Inc MKSI $294.38 $76.00 -74%
AVIC Chengdu Aircraft Company 302132 ¥57.89 ¥34.47 -40%
Fortive Corporation FTV $61.54 $33.48 -46%
Trimble Inc TRMB $57.98 $34.12 -41%
Cognex Corporation CGNX $60.67 $19.25 -68%
Wuhan Guide Infrared Co 002414 ¥13.99 ¥4.50 -68%

Compare Aplisens S.A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Aplisens S.A (APN) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 31.10 PLN versus a price of 20.30 PLN, about +53% (undervalued).
What is the fair value of APN?
Our model-based fair value for Aplisens S.A is 31.10 PLN (as of Aug 13, 2026), built from audited fundamentals. The current price is 20.30 PLN.
What is the quality score of APN?
Aplisens S.A has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Aplisens S.A (APN)?
Aplisens S.A reported trailing-twelve-month revenue of about 147M PLN (latest available figure, as of Aug 13, 2026).
What is the net profit margin of APN?
The net profit margin of Aplisens S.A is about 10.4%, meaning it keeps roughly 10.4% of revenue as net income. Based on the latest reported figures.
Does Aplisens S.A pay a dividend?
Aplisens S.A currently shows a dividend yield of about 4.89% relative to its recent price (as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Aplisens S.A and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.